Neurocarrus Inc

Neurocarrus is a pre-clinical biotechnology company developing targeted protein therapeutics for pain management and neurological disorders without addiction risk. Its Apollo drug delivery platform engineers proteins to target and deliver therapeutics directly to selected tissues and cells. Lead assets include N-001 for acute surgical pain, NL-17 for migraine prevention, and N-19a for chronic pain — all designed to provide lasting relief without opioid-associated side effects. The company is backed by NIH SBIR grants and has partnered with Stanford University and the VA Palo Alto Medical Center.